Ansa Biotechnologies has secured $54.4 million in Series B financing, led by Cerberus Ventures. The funding will enable the company to scale its DNA synthesis services to meet increasing demand.

Oct 01, 2025•10 days ago

Amount Raised

$54.4 Million

Round Type

series b

EmeryvilleBiotechnology

Investors

Black Opal VenturesAim13Fall Line CapitalAltitude Life Science VenturesBlue Water Life Science AdvisorsCerberus Ventures

Description

Ansa Biotechnologies has closed $45.2 million and secured commitments for an additional $9.2 million in an oversubscribed Series B round led by Cerberus Ventures. This funding will allow Ansa to expand its manufacturing capacity and enhance customer experience. New board members from Cerberus Ventures and Fall Line Capital will aid Ansa's strategic goals. The investment supports the company's mission to redefine DNA synthesis standards.

Company Information

Company

Ansa Biotechnologies

Location

1198 65TH STREET #250

Emeryville, California, United States

About

Ansa Biotechnologies is developing a novel way to synthesize DNA that accelerates innovation in medicine, agriculture, and industrial biotechnology. Its fast, clean, and accurate enzymatic DNA synthesis process produces gene-length molecules directly, overcoming the bottlenecks of traditional DNA synthesis methods. The company envisions a future where its technology empowers scientists to create solutions for some of the world’s biggest challenges in health and sustainability.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends